A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis
Clinical trial NCT05052983 · COMPLETED
Trial details
- NCT number
- NCT05052983
- Sponsor
- Galderma R&D
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-24
- Primary completion
- 2023-09-11
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.